Antabio
Clinical-stage biopharma developing antibiotics for multidrug-resistant hospital infections in wards and ICUs
Highlights
- New on EvolcAdded 2026-11-02
About Antabio
Antabio is a privately held, clinical-stage biopharmaceutical company developing novel antibacterials against drug-resistant pathogens that the WHO and CDC list as critical priorities. Its lead program, Meropenem-Pilabactam (MEM-PIL), is a β-lactam/β-lactamase inhibitor combination designed to treat multidrug-resistant infections in hospital wards and ICUs.
The pipeline also includes Pseudomonas Elastase Inhibitors (PEi) for chronic respiratory diseases and two discovery platforms, one run in collaboration with GARDP. A Phase 1 clinical study of MEM-ANT3310 was completed in September 2024. The company is supported by the AMR Action Fund, EIC Fund, BNP Paribas Développement, Turenne/Relyens Santé and IRDI Capital Investment.
Antabio is headquartered in Labège, France, and was founded in 2009. Its leadership team includes a CEO, CMO, CFO and CSO, and it presents its work at conferences such as IDWeek and BIO-Europe.
Product: Meropenem-Pilabactam (MEM-PIL), a β-lactam/β-lactamase inhibitor combination for multidrug-resistant hospital infections, in clinical development.
Jobs at Antabio
Leadership
- Marc Lemonnier · Chief Executive OfficerSource: company website
- Gordon Waldron · Chief Financial OfficerSource: company website
- Rienk Pypstra · Chief Medical OfficerSource: company website
- Jingjing Sun · Global Head of Business DevelopmentSource: company website
More biotech & pharma companies
Apmonia Therapeutics
Develops peptide-based cancer therapies targeting the tumor microenvironment for patients with cancerNew on EvolcAqemia
AI drug discovery company using physics-based algorithms and generative AI to design and optimise drug moleculesNew on EvolcRemote-friendlyAtlantic Bone Screen
Preclinical contract research services for pharmaceutical, biotech, biomaterials and nutraceutical developersNew on EvolcB Cell Design
Human Fc monoclonal antibodies and development services for diagnostic and biopharmaceutical companiesNew on EvolcBforcure
Point-of-need microorganism analysis instruments and PCR design software for medical, food, water and agriculture labsNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Backend
- PHPHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerx-powered-by
- Response headerx-powered-by
- Response headerx-powered-by
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- ApacheHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.